Guardant Health, Inc. Common Stock (GH) Valuation
Historical valuation analysis based on 500 data points (2024-09-25 to 2026-09-23)
Guardant Health, based in Redwood City, California, is a leader in liquid-based cancer tests for clinical and research use. The company's main franchises are Guardant360 for genomic profiling of tu...
Guardant Health, Inc. Common Stock (GH) currently trades at a P/S ratio of 21.43 (range: 3.57–22.25, 99th percentile — expensive relative to its history).
Guardant Health, Inc. Common Stock trades well above its own historical valuation range across most metrics.
Historical Valuation Metrics
| Metric | Current | Min | Median | Max | Percentile | Assessment |
|---|---|---|---|---|---|---|
| P/S Ratio | 21.43 | 3.57 | 9.00 | 22.25 | 99th | expensive relative to its history |
Guardant Health, Inc. Common Stock (GH) Valuation & P/E History
Guardant Health, Inc. Common Stock (GH) is a US-listed stock operating in the Healthcare sector, specifically the Services-Medical Laboratories industry currently trading at $175.05 with a market capitalization of $23.5 billion. This page provides historical valuation analysis for GH based on 500 data points covering 2024-09-25 to 2026-09-23.. The P/S ratio of 21.43 compares to a median of 9.00.
GH Valuation Metrics & Historical Range
The valuation table above shows Guardant Health, Inc. Common Stock's current and historical valuation multiples, including P/E ratio, P/S ratio, EV/EBITDA, FCF yield, and dividend yield. Each metric is compared to its own historical range to determine whether GH is currently trading above or below its typical valuation levels.
- P/E ratio: Price-to-earnings measures how much investors pay per dollar of earnings. A P/E above the historical median suggests GH is expensively valued; below the median suggests it is cheap.
- P/S ratio: Price-to-sales is useful for companies with volatile or negative earnings. Lower P/S relative to history may indicate value.
- EV/EBITDA: Enterprise value to EBITDA adjusts for debt and cash, providing a capital-structure-neutral valuation measure for Guardant Health, Inc. Common Stock.
- FCF yield: Free cash flow yield shows the cash return relative to market price. Higher yields may indicate undervaluation.
Is GH Overvalued or Undervalued?
Guardant Health, Inc. Common Stock trades well above its own historical valuation range across most metrics. The overall valuation percentile of 99 combines P/E, P/S, and EV/EBITDA percentiles into a single measure of how expensive GH is relative to its own history. A percentile below 25 suggests the stock may be undervalued, while a percentile above 75 suggests it may be overvalued.
However, valuation is only one factor in investment decisions. A stock can remain "overvalued" for years if growth accelerates, or "undervalued" if the business deteriorates. Always combine valuation analysis with financial statement analysis and the full GH analysis page for a complete picture.
Valuation data is computed from historical price and fundamental data via Polygon.io and Finnhub.GH trades on NYSE/NASDAQ. This page is for informational purposes only and is not financial advice.